Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Charles River Laboratories Intl (CRL)

Charles River Laboratories Intl (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Charles River Laboratories Intl 251 BALLARDVALE STREET WILMINGTON MA 01887 USA

www.criver.com Employees: 21,800 P: 781-222-6000

Description:

Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.

Key Statistics

Overview:

Market Capitalization, $K 9,421,625
Enterprise Value, $K 11,848,725
Shares Outstanding, K 51,631
Annual Sales, $ 4,129 M
Annual Net Income, $ 474,620 K
Last Quarter Sales, $ 1,026 M
Last Quarter Net Income, $ 94,080 K
EBIT, $ 695,140 K
EBITDA, $ 1,009 M
60-Month Beta 1.38
% of Insider Shareholders 1.30%
% of Institutional Shareholders 98.91%
Float, K 50,960
% Float 98.70%
Short Volume Ratio 0.63

Growth:

1-Year Return 0.31%
3-Year Return -52.71%
5-Year Return 31.21%
5-Year Revenue Growth 82.23%
5-Year Earnings Growth 76.95%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 2.80 on 08/07/24
Next Earnings Date 11/06/24 [BMO]
Earnings Per Share ttm 10.25
EPS Growth vs. Prev Qtr 23.35%
EPS Growth vs. Prev Year 4.09%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CRL Ratios

Ratio
Price/Earnings ttm 17.65
Price/Earnings forward 17.84
Price/Earnings to Growth 6.12
Return-on-Equity % 14.96%
Return-on-Assets % 6.70%
Profit Margin % 11.49%
Debt/Equity 0.65
Price/Sales 2.26
Price/Cash Flow 10.62
Price/Book 2.47
Book Value/Share 72.19
Interest Coverage 5.25
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar